Aaron recently helped a PI with an emerging pharmaceutical company to win a $1.1 million SBIR Phase II grant from the National Institutes of Health (NIH) to advance their cancer research. The company is developing a theranostic target that has both diagnostic and therapeutic applications and acts as driver of tumorigenesis. The resulting therapeutic drug will benefit two high-risk Breast Cancer (BC) populations for whom there are no/ limited effective treatment choices: hormone therapy resistant ER+ (HRBC) and triple negative BC (TNBC) whose tumors lack ER, PR and Her-2 receptors. The two companion diagnostics (CDx) which are being simultaneously developed have potential to benefit all BC patients, thus further improving commercialization potential. By addressing drug resistant BC there is potential to change the treatment paradigm for one of the major cancers affecting patients, with over 200,000 new cases each year and 40,000 deaths.
The company partnered with Aaron to modify their Commercialization Plan for the Phase II component of their Fast Track application, and to assist with their Phase I progress report.